SCHEDULE: Biofrontera AG Updates Stake in Biofrontera Inc. with New Licensing Deal and Preferred Stock Issuance

Sentiment:

Beneficial Ownership Update 25 July 2025 2:31 PM

Biofrontera AG and related entities updated their beneficial ownership in Biofrontera Inc. following a new agreement for U.S. rights to Ameluz and RhodoLED, involving a royalty structure and the issuance of convertible preferred stock.

Delay expectedThe conversion of BFAG's 3,019 shares of Series D Preferred Stock into 4,831,172 shares of common stock is contingent upon the Issuer's stockholders approving the issuance of the Series D Preferred Stock and the underlying common shares. This introduces a potential delay to BFAG fully realizing its increased ownership.

Capital raiseBiofrontera Inc. issued 3,019 shares of Series D Convertible Preferred Stock to Biofrontera AG as part of an agreement to acquire U.S. rights to Ameluz and RhodoLED. This is a form of capital transaction, exchanging assets for equity.

Summary

Biofrontera AG (BFAG) and its subsidiaries entered an agreement with Biofrontera Inc. (the Issuer) on June 30, 2025, transferring U.S. rights to Ameluz and RhodoLED to the Issuer.
The new agreement replaces a previous transfer pricing model with a royalty structure: 12% royalty when U.S. Ameluz revenue is less than $65.0 million, and 15% when it exceeds $65.0 million.
BFAG received 3,019 shares of the Issuer's Series D Convertible Preferred Stock, convertible into 4,831,172 shares of common stock, contingent on Issuer stockholder approval.
BFAG's beneficial ownership in Biofrontera Inc. currently stands at 4.23% (400,000 shares), significantly diluted from approximately 69.0% post-IPO due to subsequent equity issuances and a 1-for-20 reverse stock split.
Deutsche Balaton Aktiengesellschaft (DB) and related entities beneficially own 4.86% (458,884 shares), including shares held by BFAG.
An ongoing legal proceeding in Germany, initiated by DB against BFAG, challenges the approval of the Issuer's IPO.

Sentiment

Score: 6

Explanation: The filing clarifies a significant strategic transaction and ownership structure. While past dilution was negative, the new agreement and potential for increased ownership for BFAG are positive developments for that entity. The ongoing litigation and contingency on stockholder approval introduce some uncertainty, but overall, it provides clarity on a complex relationship.

Positives

The new royalty agreement provides a clear revenue stream for BFAG from the U.S. rights to Ameluz and RhodoLED.
The issuance of Series D Preferred Stock to BFAG, convertible into 4,831,172 common shares, offers a significant potential increase in BFAG's ownership stake in Biofrontera Inc. upon stockholder approval.
BFAG will have the right to appoint one or two members to Biofrontera Inc.'s board of directors for three years, enhancing its influence.

Negatives

BFAG's ownership in Biofrontera Inc. has been substantially diluted from approximately 69.0% post-IPO to 4.23% due to the Issuer's repeated equity issuances and a reverse stock split.
The agreement includes a transfer of all costs associated with the U.S. business to BFAG, which could impact BFAG's profitability.
An ongoing legal dispute in Germany challenges the validity of BFAG's board resolutions regarding Biofrontera Inc.'s IPO.

Risks

Conversion of the Series D Preferred Stock into common stock is contingent on Biofrontera Inc.'s stockholder approval, introducing uncertainty regarding BFAG's increased ownership.
The ongoing legal proceeding in Germany regarding the validity of BFAG's IPO approval could have unforeseen implications.
Future acquisitions or dispositions of Biofrontera Inc. securities by Deutsche Balaton Aktiengesellschaft are subject to market conditions and may impact share price volatility.

Future Outlook

Deutsche Balaton Aktiengesellschaft (DB) currently intends to acquire additional voting securities of Biofrontera Inc., or instruments convertible into voting securities, for investment purposes, subject to market conditions. Biofrontera AG (BFAG) expects to become a beneficial owner of more than five percent of Biofrontera Inc.'s common stock upon receiving stockholder approval for the conversion of its Series D Preferred Stock.

Management Comments

There is no agreement among the Reporting Persons, written or oral, with respect to the acquisition, ownership, voting or disposition of any securities of the Issuer, and the Reporting Persons disclaim the existence of any group among them within the meaning of Section 13(d)(3) of the Act or the rules and regulations of the Securities and Exchange Commission ("SEC") promulgated thereunder.
DB purchased the shares of common stock reported on this Amendment No. 3 to Schedule 13D for investment purposes. In addition, DB sought to offset in part the economic dilution resulting to BFAG (and, indirectly, to BFAG's shareholders) as a result of the Issuer's repeated issuances of common stock and warrants.

Industry Context

This filing details a significant inter-company licensing and ownership restructuring within the biopharmaceutical sector, specifically for dermatological products. It reflects strategic adjustments between a parent company (BFAG, formerly sole owner) and its spun-off U.S. subsidiary (Biofrontera Inc.) to optimize revenue streams and ownership stakes following a period of dilution.

Comparison to Industry Standards

The royalty structure (12-15% of revenue) for pharmaceutical product rights is within the typical range for licensing agreements in the biopharmaceutical industry, which can vary widely based on development stage, market potential, and negotiation leverage.
The issuance of convertible preferred stock as consideration for asset transfers is a common mechanism in corporate transactions, particularly when a strategic investor or former parent seeks to maintain or regain influence and economic interest.
The significant dilution experienced by the former parent company (BFAG) from 69% to 4.23% post-IPO, followed by attempts to offset this through new agreements and preferred stock, highlights a common challenge in spin-offs or partial divestitures where the subsidiary pursues independent capital raises.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Appointment Rights	For three years following June 30, 2025, Biofrontera AG (BFAG) will have the right to appoint one member to Biofrontera Inc.'s board of directors if the board has up to seven members, and two members if the board has eight or more, contingent on BFAG holding Series D Preferred Stock or converted common stock.	2025-06-30	Increases BFAG's influence and representation on Biofrontera Inc.'s board, aligning governance with its strategic interest.

Legal Proceedings

Deutsche Balaton Aktiengesellschaft (DB) filed an action against Biofrontera AG (BFAG) with the local court of Cologne, Germany, arguing that the listing of Biofrontera Inc.'s common stock on NASDAQ and the issuance of common stock as part of the IPO required approval at BFAG's general meeting.
The local court of Cologne ruled that BFAG's board resolutions regarding the IPO of Biofrontera Inc. are void because BFAG had to obtain its general meeting's approval.
Former board members and supervisory board members of BFAG lodged an appeal against this ruling to the Higher Regional Court of Cologne, Germany.
The Higher Regional Court of Cologne, Germany rejected the litigation but permitted an appeal to the Federal Supreme Court. DB has not yet decided whether to pursue this appeal.

Related Party Transactions

An agreement was signed on June 30, 2025, between Biofrontera AG (BFAG) and its subsidiaries, and Biofrontera Inc., where Biofrontera Inc. acquired U.S. rights to Ameluz and RhodoLED.
As part of this agreement, Biofrontera Inc. will pay royalties to BFAG (12% or 15% based on Ameluz revenue) and BFAG received 3,019 shares of Series D Convertible Preferred Stock from Biofrontera Inc.
The agreement also includes a transfer of all costs associated with the U.S. business to BFAG.

Stakeholder Impact

Shareholders of Biofrontera Inc.: Will be asked to approve the issuance of Series D Preferred Stock and the underlying common shares, which could lead to significant dilution if approved and converted.
Shareholders of Biofrontera AG: Indirectly impacted by the new royalty stream and the potential increase in BFAG's stake in Biofrontera Inc., which aims to offset previous dilution.
Management of Biofrontera Inc.: The new board appointment rights for BFAG could alter board dynamics and strategic direction.

Next Steps

Biofrontera Inc. stockholders need to approve the issuance of the Series D Preferred Stock and the common stock issuable upon conversion.
Deutsche Balaton Aktiengesellschaft may acquire additional voting securities of Biofrontera Inc.
Biofrontera AG may convert its Series D Preferred Stock into common stock upon stockholder approval.
Deutsche Balaton Aktiengesellschaft will decide whether to appeal the Higher Regional Court of Cologne's ruling to the Federal Supreme Court regarding the IPO approval litigation.

Key Dates

Date	Description
2021-11-02	Biofrontera Inc. consummated its initial public offering (IPO).
2021-12-13	Deutsche Balaton Aktiengesellschaft (DB) filed an action against Biofrontera AG (BFAG) with the local court of Cologne, Germany, arguing that the Issuer's NASDAQ listing and IPO required BFAG's general meeting approval.
2023-07-03	Biofrontera Inc. effected a 1-for-20 reverse stock split of its outstanding common shares.
2024-02-13	Effective date of the Second Amended and Restated License and Supply Agreement between the Issuer, BFAG, and BFAG's subsidiaries.
2024-12-20	Amendment No. 2 to Schedule 13D filed by BFAG and related parties.
2025-05-13	Date as of which 9,446,197 shares of common stock were outstanding, as reported in the Issuer's Form 10-Q.
2025-05-15	Date the Issuer's Quarterly Report on Form 10-Q was filed.
2025-06-30	BFAG and its subsidiaries signed an agreement with Biofrontera Inc. for the acquisition of U.S. rights to Ameluz and RhodoLED, and the effective date of the new royalty agreement.
2025-07-25	Signing date of the Power of Attorney and the Schedule 13D Amendment No. 3.

Recommendation

hold

This filing primarily provides an update on the complex ownership structure and a significant licensing agreement between Biofrontera AG and Biofrontera Inc. While the potential for Biofrontera AG to significantly increase its stake in Biofrontera Inc. through the Series D Preferred Stock conversion is notable, it is contingent on stockholder approval. The new royalty structure provides clarity on future revenue streams for Biofrontera AG. However, the ongoing litigation and the historical dilution experienced by Biofrontera AG add layers of complexity and uncertainty. Without more comprehensive financial performance data or a clear strategic shift beyond this restructuring, a "hold" recommendation is appropriate, suggesting investors maintain their current position while monitoring the outcome of the stockholder vote and the ongoing legal proceedings.

Keywords

Biofrontera Inc., Biofrontera AG, Schedule 13D, beneficial ownership, Ameluz, RhodoLED, Series D Preferred Stock, royalty agreement, biopharmaceutical, dermatology, SEC filing, corporate governance, litigation, stock dilution

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.